PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

Obesity Clinical Trial

— PGC-1  

Official title:

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02282423
• Other study ID #: 13-006411
• Status: Recruiting
• Phase: N/A
• First received: October 29, 2014
• Last updated: January 14, 2016
• Start date: May 2014
• Est. completion date: January 2018

Study information

• Verified date: January 2016
• Source: Mayo Clinic
• Contact: Nora Drutz, RN
• Phone: 480-301-4626
• Email: ARZClinicalStudies[@]mayo.edu
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to understand how and why insulin resistant individuals respond differently to exercise as compared with insulin sensitive individuals at the skeletal muscle and gene expression level.

Description:

The goal of this study is to understand how and why insulin resistant individuals respond differently to exercise as compared with insulin sensitive individuals at the skeletal muscle and gene expression level. The study has four aims including testing if MZF1, NFKB1, RELA, SP1/KLF and EGRI expression responses are outside of the normal range in insulin resistant individuals and how insulin resistance changes the cell biosynthesis process/ post translational modifications. It also aims to define the response of MiRNAs in healthy and insulin resistant individuals and determine if treatment with Gemfibrozil inhibits transcription processes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 96
• Est. completion date: January 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 30 Years to 59 Years

Eligibility

Inclusion Criteria: Aims1-3

1. Age 30-59

2. BMI: Lean, BMI less than or equal to 25; Obese, BMI between 30-40; type 2 diabetic, BMI between 30-40.

3. Subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.

4. Subjects may be of either sex with age as described in each protocol. Female subjects must be non-lactating and will be eligible only if they have a negative pregnancy test throughout the study period.

5. Subjects must range in age as described in each specific protocol.

6. Subjects must have the following laboratory values:

• Hematocrit = 35 vol%

• Serum creatinine = 1.6 mg/dl

• AST (SGOT) < 2 times upper limit of normal

• ALT (SGPT) < 2 times upper limit of normal

• Alkaline phosphatase < 2 times upper limit of normal

• Triglycerides < 150 mg/dl (except for Aim 4).

Aim 4

1. Age 30-59

2. BMI: Lean, BMI less than or equal to 25; Obese, BMI between 30-40.

3. Patients may have normal or impaired glucose tolerance.

4. Subjects must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.

5. Subjects may be of either sex with age as described in each protocol. Female subjects must be non-lactating and will be eligible only if they have a negative pregnancy test throughout the study period.

6. Subjects must have the following laboratory values:

• Hematocrit = 35 vol%

• Serum creatinine = 1.6 mg/dl

• AST (SGOT) < 2 times upper limit of normal

• ALT (SGPT) < 2 times upper limit of normal

• Alkaline phosphatase < 2 times upper limit of normal

• Triglycerides > 300 mg/dl for nondiabetics, > 250 mg/dl for impaired glucose tolerance.

Exclusion Criteria:

1. Subjects must not be receiving any of the following medications: thiazide or furosemide diuretics, beta-blockers, or other chronic medications with known adverse effects on glucose tolerance levels unless the patient has been on a stable dose of such agents for the past three months before entry into the study. Subjects may be taking a stable dose of estrogens or other hormonal replacement therapy, if the subject has been on these agents for the prior three months. Subjects taking systemic glucocorticoids are excluded. Patients with type 2 diabetes will be excluded if they are taking metformin or thiazolidinediones, but may be taking sulfonylureas or other medications known to work through effects on insulin secretion.

2. Subjects receiving Gemfibrozil must not also be receiving a statin.

3. Subjects with a history of clinically significant heart disease (New York Heart Classification greater than grade II; more than non-specific ST-T wave changes on the EKG), peripheral vascular disease (history of claudication), or pulmonary disease (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation) will not be studied.

4. Recent systemic or pulmonary embolus, untreated high-risk proliferative retinopathy, recent retinal hemorrhage, uncontrolled hypertension, systolic BP>180, diastolic BP>105, autonomic neuropathy, resting heart rate >100, electrolyte abnormalities.

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Diabetes
• Obesity

Intervention

Behavioral:
• Pre-study dietary and exercise instruction.
All subjects will be instructed to continue their normal diet during the three days prior to study, to not consume alcohol the day before study, and to not engage in exercise for 48 hours before all studies.

Procedure:
• Screening examination and oral glucose tolerance test
All subjects will have screening exam and OGTT at the Clinical Studies Infusion Unit at Mayo Clinic in Arizona at 7-8 am after having eaten nothing after 10 PM the night before, and have a screening examination and 75 g OGTT, as described
• Euglycemic clamp
On a separate day, subjects will have a two-hour euglycemic clamp ((80 mU insulin/(m2.min)) at the Clinical Studies Unit at Mayo Clinic Arizona at 7-8 am after an overnight fast. A muscle biopsy will be taken before the insulin infusion, to serve as the resting biopsy (3). Biopsy specimens (150-300 mg) will be frozen immediately in liquid nitrogen and stored in liquid nitrogen until they are processed
• VO2max.
VO2max.

Behavioral:
• Acute exercise bout
The single acute exercise bout will be performed as described (3). It consists of 4 sets of 12 min each (8 min @ 70% VO2max, 2 min @ 90%, 2 min rest, repeat X 4). Biopsies are taken 30 min and 24 hr after end of exercise. Resting biopsies are taken on the glucose clamp day

Procedure:
• Percutaneous needle muscle biopsies
Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing. We routinely obtain 150-300 mg muscle (wet weight), which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein, as described (2, 3, 12).

Locations

Country	Name	City	State
United States	Mayo Clinic	Scottsdale	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	Arizona State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Transcription Factor Response to Exercise	To determine whether expression of the transcription factor MZF1 is induced by exercise to a greater degree in control patients than in those with type 2 diabetes mellitus. MZF1 expression will be determined using quantitative rt-PCR analysis on RNA isolated from muscle biopsies taken from the patients. An repeated measures analysis of variance will be performed on the PCR data, for the three groups (lean, obese, type 2 diabetic), with the difference between the lean and diabetic groups being the primary measure. A P value of 0.05 will be considered significant.	4-6 weeks	No